With Henrique Arfsten, Medical University of Vienna, Vienna - Austria and Alexandre Mebazza, Hospital Lariboisiere, Paris - France. 

In this episode of HFA CardioTalk, Henrike Arfsten and  Alexandre Mebazaa discuss the importance of rapid initiation and titration of guideline-directed medical heart failure therapy.

A focus will be on data from the STRONG-HF trial, which demonstrated safety and efficacy of rapid up-titration following an acute heart failure event. The trial was even stopped early as the benefits of the intensive treatment strategy were overwhelming. Moreover, specific questions are raised, such as the right time to start therapy and how to deal with possible side effects.

Mebazaa A, et al. Lancet 2022 Dec 3;400(10367):1938-52

Biegus J, et al. Heart Fail Rev 2024 Sep;29(5):1065-1077

McDonagh TA, et al. Eur J Heart Fail 2022 Jan;24(1):4-131

McDonagh TA, et al. Eur J Heart Fail 2024 Jan;26(1):5-17

This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of an unrestricted financial support. The discussion has not been influenced in any way by its sponsor.